Evidence map›Paper›PMID 21310852›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2011

Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.

Jie Xu, Yue Zhang, Philip A Berry, Jing Jiang, Peter E Lobie, John F Langenheim, Wen Y Chen, Stuart J Frank

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Early Investigations of 20-kDa Human Placental GH Show Promise.Endocrine, metabolic & immune disorders drug targets · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Classical and novel GH receptor signaling pathways.Molecular and cellular endocrinology · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Genome-wide pathway analysis of breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jie XuDepartment of Medicine, University of Alabama at Birmingham, Alabama 35294-0012, USA.
Yue Zhang
Philip A Berry
Jing Jiang
Peter E Lobie
John F Langenheim
Wen Y Chen
Stuart J Frank
University of Alabama at Birmingham · USClemson University · USBirmingham VA Medical Center · USNational University Cancer Institute, Singapore · SG

Funding

TRAINING IN CELLULAR PHYSIOLOGY MEMBRANE TRANSPORTT32DK007545 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M · 1987 to 2023
$4.5M
Growth Hormone Receptor Dimerization/Disulfide LinkageR01DK058259 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J · 2001 to 2014
$3.4M
Growth Hormone Receptor Dimerization/Disulfide LinkageR56DK058259 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRANK, STUART J · 2010 to 2010
$220k
NIDDK NIH HHS DK58259NIDDK NIH HHS R01 DK058259NIDDK NIH HHS R56 DK058259NIDDK NIH HHS T32 DK007545
6 · The paper itself

Abstract

GH receptor (GHR) and prolactin (PRL) receptor (PRLR) are structurally similar cytokine receptor superfamily members that are highly conserved among species. GH has growth-promoting and metabolic effects in various tissues in vertebrates, including humans. PRL is essential for regulation of lactation in mammals. Recent studies indicate that breast tissue bears GHR and PRLR and that both GH and PRL may impact development or behavior of breast cancer cells. An important facet of human GH (hGH) and human PRL (hPRL) biology is that although hPRL interacts only with hPRLR, hGH binds well to both hGHR and hPRLR. Presently, we investigated potential signaling effects of both hormones in the estrogen receptor- and progesterone receptor-positive human T47D breast cancer cell line. We found that this cell type expresses ample GHR and PRLR and responds well to both hGH and hPRL, as evidenced by activation of the Janus kinase 2/signal transducer and activator of transcription 5 pathway. Immunoprecipitation studies revealed specific GHR-PRLR association in these cells that was acutely enhanced by GH treatment. Although GH caused formation of disulfide-linked and chemically cross-linked GHR dimers in T47D cells, GH preferentially induced tyrosine phosphorylation of PRLR rather than GHR. Notably, both a GHR-specific ligand antagonist (B2036) and a GHR-specific antagonist monoclonal antibody (anti-GHR(ext-mAb)) failed to inhibit GH-induced signal transducer and activator of transcription 5 activation. In contrast, although the non-GHR-specific GH antagonist (G120R) and the PRL antagonist (G129R) individually only partially inhibited GH-induced activation, combined treatment with these two antagonists conferred greater inhibition than either alone. These data indicate that endogenous GHR and PRLR associate (possibly as a GHR-PRLR heterodimer) in human breast cancer cells and that GH signaling in these cells is largely mediated by the PRLR in the context of both PRLR-PRLR homodimers and GHR-PRLR heterodimers, broadening our understanding of how these related hormones and their related receptors may function in physiology and pathophysiology.

Indexed as

Signal TransductionBreast NeoplasmsCell Line, TumorFemaleGrowth HormoneHumansImmunoprecipitationJanus Kinase 2PhosphorylationProlactinReceptors, ProlactinReceptors, SomatotropinSTAT5 Transcription FactorGrowth HormoneJanus Kinase 2ProlactinReceptors, ProlactinReceptors, SomatotropinSTAT5 Transcription Factor

Identifiers

PMID21310852
PMCPMC3063080
OpenAlexW2040160058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.